What is Calidi Biotherapeutics, Inc. (CLDI)?

Calidi Biotherapeutics, Inc. (CLDI) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of CLDI?

The current price of CLDI is $0.70. Prices are updated in real time on Stocks360.

What is CLDI's price-to-earnings (PE) ratio?

CLDI's trailing twelve-month PE ratio is -0.01, based on current price and earnings per share data available on Stocks360.

What is CLDI's market capitalization?

CLDI's market capitalization is $1,813,580.00, placing it in the small-cap tier.

Calidi Biotherapeutics, Inc. (CLDI)

Stock analysis · AMEX · Healthcare · Biotechnology

$0.70

Market Cap

$1.81M

PE (TTM)

-0.01

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.33

Day Range

$0.66 – $0.72

52-wk Range

$0.62 – $27.04

Avg Volume

N/A

Volume

27.53K

Calidi Biotherapeutics, Inc. (CLDI) is a publicly traded company in the Healthcare sector. Latest price: $0.70. Market cap $1.81M. Trailing PE -0.01. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $23.84 2026-10-28 · $0.70 (-97.06%)

Earnings

Most Recent

Mar 27, 2026

EPS $-9.12 vs est. $-24.96

Beat by $15.84

Next Earnings

Nov 17, 2026

EPS estimate $0.00

Proprietary Signals

Signal snapshot temporarily unavailable.

About Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, Cal…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.01×
P/S (TTM)	0.00×
P/B	0.32×
P/FCF (TTM)	-0.10×
EV / EBITDA	0.02×
EV / Sales	0.00×
Earnings Yield	-1758.29%
Free Cash Flow Yield	-981.87%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$315.42K
Net Income (TTM)	-$31.89M
Free Cash Flow (TTM)	-$17.65M
Net Debt	-$2.13M
Working Capital	$2.19M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-372.86%
Return on Invested Capital	-347.09%